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The genus Burkholderia consists of diverse species which includes both “friends”
and “foes.” Some of the “friendly” Burkholderia spp. are extensively used in the
biotechnological and agricultural industry for bioremediation and biocontrol. However,
several members of the genus including B. pseudomallei, B. mallei, and B. cepacia, are
known to cause fatal disease in both humans and animals. B. pseudomallei and B. mallei
are the causative agents of melioidosis and glanders, respectively, while B. cepacia
infection is lethal to cystic fibrosis (CF) patients. Due to the high rate of infectivity and
intrinsic resistance to many commonly used antibiotics, together with high mortality
rate, B. mallei and B. pseudomallei are considered to be potential biological warfare
agents. Treatments of the infections caused by these bacteria are often unsuccessful
with frequent relapse of the infection. Thus, we are at a crucial stage of the need for
Burkholderia vaccines. Although the search for a prophylactic therapy candidate continues,
to date development of vaccines has not advanced beyond research to human clinical
trials. In this article, we review the current research on development of safe vaccines with
high efficacy against B. pseudomallei, B. mallei, and B. cepacia. It can be concluded that
further research will enable elucidation of the potential benefits and risks of Burkholderia
vaccines.
Keywords: Burkholderia pseudomallei, Burkholderia mallei, Burkholderia cepacia, melioidosis, glanders, cystic
fibrosis, vaccine
Burkholderia spp.
The genus Burkholderia is a phylogenetically coherent genus con-
sisting of interesting and complex bacterial taxonomy which
includes a wide variety of Gram-negative, bacilli (1–5μm length
and 0.5–1.0μm width), that are motile due to the presence of
multi-trichous polar flagella (Vandamme et al., 2007). These
bacteria are generally obligate aerobes and commonly found in
the soils of all temperatures including the Arctic soil at tem-
perature of 7◦C (Master and Mohn, 1998) and in groundwater
worldwide (Ussery et al., 2009). The genomic G + C content of
Burkholderia spp. ranges between 64% and 68.3% (Yabuuchi et al.,
1992). Members of the genus Burkholderia were formerly clas-
sified as belonging to the genus of Pseudomonas which belongs
to the Proteobacteria homology group II (Yabuuchi et al., 1992).
The taxonomy of the genus Burkholderia has undergone con-
siderable changes since it was first reported, when 22 validly
described species were included (Coenye et al., 2001). Currently,
the Burkholderia genus comprises at least 43 species, which are
extremely diverse and versatile (Vial et al., 2007; Compant et al.,
2008).
Members of the genus Burkholderia can form associations
with plants and are also able to cause disease in animals and
humans. There are two main factors that can be attributed to
the ecological versatility of the members of this genus which
includes: (1) the huge coding capacity of their large multirepli-
con genomes (6–9Mb) that allow the members of the genus to
be metabolically robust; and (2) an array of insertion sequences
in their genomes which promote genomic plasticity and general
adaptability (Lessie et al., 1996). Their survival and persistence,
in the environment and in host cells, offers a notable example of
bacterial adaptation (Woods and Sokol, 2006).
Several members of the genus are used in a variety of
biotechnological applications, including bioremediation, bio-
logical control of plant diseases, water management, and also
improvement of nitrogen fixation (Parke and Gurian-Sherman,
2001). Although most of the species in the genus Burkholderia
are not pathogenic for healthy individuals, a few that include
B. pseudomallei, B. mallei, and B. cepacia, are capable of causing
severe, life-threatening infections in both normal and immuno-
compromised individuals. Some of these infections are inherently
difficult to treat due to the resistance of these bacteria to multi-
ple antibiotics, the ability to form biofilms, and the establishment
of intracellular and chronic infection stages in the host (George
et al., 2009).
Preventive measures such as the use of vaccines for active
immunization could offer significant protection to persons liv-
ing in endemic areas and reduce the worldwide incidence of
Burkholderia infections. In addition, the range of infections
caused by Burkholderia spp. and the potential to develop chronic
infections in the immunocompromised host through the persis-
tent nature of these bacteria makes the need for a vaccine crucial.
In recent years, many studies have been performed in order
to identify vaccine strategies against B. pseudomallei, B. mallei,
and B. cepacia, but to date no ideal candidate has yet emerged
(Sarkar-Tyson and Titball, 2010). The most important reason for
the failure to identify a good vaccine is due in the main to the
Frontiers in Cellular and Infection Microbiology www.frontiersin.org February 2013 | Volume 3 | Article 5 | 1
CELLULAR AND INFECTION MICROBIOLOGY
Choh et al. Burkholderia vaccines
intracellular nature of these pathogens which makes it difficult to
evoke both an antibody response and also strong cellular-based
responses.
Burkholderia pseudomallei
B. pseudomallei is endemic in the soils of southeast Asia and
northern Australia and have been reported to occur in other
tropical and subtropical regions, worldwide. The bacterium is
now classified as Category B priority agent and the disease
caused is known as melioidosis which was first described as a
“glanders-like” disease among morphine addicts by Whitmore
and Krishnasawami in Rangoon, Burma in 1911 (Whitmore,
1913; Whitmore and Krishnaswami, 2012).
Melioidosis presents as a broad range of conditions from acute
fulminant pneumonia and septicemia acquired by inhalation to
wound infections acquired through inoculation of the bacteria
from soil through skin abrasion (Currie et al., 2000; Dance, 2002).
B. pseudomallei also poses a worldwide emerging infectious dis-
ease problem and a bioterrorism threat due to its severe course
of infection, aerosol infectivity, low infectious dose, an intrin-
sic resistance to commonly used antibiotics, lack of a currently
available vaccine, and the worldwide availability (Stevens et al.,
2004).
Pathogenesis of the disease has been demonstrated to include
the ability of B. pseudomallei to escape into the cytoplasm
from endocytic vacuoles of the host cells, where it can poly-
merize actin and subsequently spread from one cell to another
(Kespichayawattana et al., 2000; Breitbach et al., 2003; Stevens
et al., 2005; Boddey et al., 2007). Amajor feature of this bacterium
is the ability to remain latent in the host and cause recrudes-
cent or relapsing infections following many years past the initial
infection. This relapse of the infection is quite common despite
appropriate antibiotic therapy and the presence of high anti-
body titers in infected patients (Currie et al., 2000; Vasu et al.,
2003). Regardless of antibiotic therapy, rapid progress of acute
melioidosis to sepsis, followed by death within 48 h of clini-
cal onset has been reported (Cheng et al., 2007). Mortality rate
of patients with septic shock is reported to be approximately
80–95% (Leelarasamee, 2004).
Burkholderia thailandensis
B. thailandensis is a closely related yet distinct B. pseudoma-
llei-like organism (Brett et al., 1998). Although there is 99%
similarity of B. thailandensis genes with its virulent counter-
part, the pathogenic species B. pseudomallei, it is apparently
non-pathogenic in humans. Smith et al. (1997) have reported
that B. thailandensis demonstrated a mean 50% lethal dose of
109 cfu/mouse compared to 182 cfu/mouse for B. pseudomallei,
indicating that it is also much less virulent in animal models.
The avirulent properties of B. thailandensis might be attributed
to the presence of a complete arabinose biosynthesis operon,
which is an anti-virulence property and this is largely deleted
in the B. pseudomallei genome (Moore et al., 2004; Lazar Adler
et al., 2009). However, like B. pseudomallei, B. thailandensis also
has an intracellular lifecycle. Thus, it is often used as a model
microbe to study various aspects of the potential bioterrorism
agent B. pseudomallei and B. mallei.
Burkholderia mallei
Glanders is caused by B. mallei which typically infects solipeds,
such as horses, mules, and donkeys. B. mallei only occasionally
infect humans such as laboratory workers and personnel who are
often in close contact with infected animals (Srinivasan et al.,
2001). Due to its ability to infect via inhalation route, the bac-
terium was among the first bioweapon used during both World
Wars I and II. Since then, it has been classified as a Category B
priority agent (Wheelis, 1998).
The course of infection is reliant on the route of expo-
sure including ingestion of contaminated poultry, inhalation of
aerosol containing the bacterium and abrasion which leads to
a localized cutaneous infection. In an acute infection, general
symptoms include fever, malaise, abscess formation, pneumo-
nia, and sepsis. In cases of untreated septicemic infections, the
fatality rate is as high as 95% whereas for antibiotic-treated indi-
viduals, 50% fatality has been reported (Currie, 2009). Despite
numerous reports that indicate in vitro susceptibility of B. mallei
to a wide array of antibiotics, the in vivo efficacies are not well-
established (Kenny et al., 1999; Heine et al., 2001; Judy et al.,
2009). Although the pathogenic determinants of B. mallei have
already been defined, the pathogenesis of the bacteria is still
unknown.
Burkholderia cepacia
B. cepacia was first described as a phytopathogen with the abil-
ity to infect onion bulbs causing a condition called “soft rot”
(Burkholder, 1950). The B. cepacia complex (Bcc) is a collec-
tion of closely related species which are genotypically distinct
but phenotypically similar species. Strains originally identified as
B. cepacia were classified into at least nine genomovars, which
are referred to as the Bcc (Vandamme et al., 1997, 2000) and
more recently, another eight genomovars have been included
(Vanlaere et al., 2008, 2009). All Bcc species share a high degree of
16S rDNA sequence similarity (98–99%) and moderate levels of
whole genome DNA–DNA hybridization (30–50%) (Vandamme
et al., 1997, 2000; Vanlaere et al., 2009).
B. cepacia is naturally found in moist soil, particularly in
the rhizosphere of plant and freshwater environments in rel-
atively high population. It is now recognized as a significant
human pathogen associated with nosocomial infections, espe-
cially among cystic fibrosis (CF) patients (Cepacia syndrome) or
chronic granulomatous disease (CGD) which can lead to rapid
decline of lung function. Even with proper treatment the Cepacia
syndrome has been known to lead to death within a few weeks of
infection. CF patients might be asymptomatic carriers of B. cepa-
cia which over time can cause the infection to progress into a
necrotizing pneumonia and bacteremia. In CF patients, B. cepa-
cia infections lead on to multi-organ system dysfunction, the
most severely affected being the lower respiratory tract of the
affected patients. Person-to-person transmission from one CF
patient to another via close contact in a nosocomial environment
has been reported (Govan et al., 1993; Jones et al., 2004). There
are also other reports suggesting the involvement of B. cepacia
infections in cancer and HIV patients as well as among immuno-
competent individuals (Marioni et al., 2006; Mann et al., 2010).
B. cepacia strains have also been isolated in some cases of chronic
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suppurative otitis media, pharyngeal, and neck infections from
immonocompromised individuals as reported by Marioni et al.
(2006).
THE NEED FOR Burkholderia VACCINES
Vaccines against Burkholderia infections are necessary to offer
prophylactic protection for susceptible large populations living in
endemic areas worldwide and also for visitors to these areas (Sun
et al., 2005; Suparak et al., 2005). Through vaccination, the inci-
dence of persistent or chronic infections in the population can be
reduced. As these bacteria occur in the soil, every individual has
the potential risk to acquire these infections through routine daily
activities.
Compounding this fact, the treatment of Burkholderia infec-
tions are especially difficult due to the inherent resistance of
Burkholderia spp. to multiple antibiotics including aminoglyco-
sides, quinolones, polymyxins, and β-lactams (Aaron et al., 2000;
Martin and Mohr, 2000; Leitao et al., 2008; Estes et al., 2010).
The multi-resistance property of the Burkholderia spp. may result
from various efflux pumps that efficiently remove antibiotics
from the cell, decreased contact of antibiotics with the bacterial
cell surface due to their ability to form biofilms, and changes in
the cell envelope that reduce the permeability of the membrane
to the antibiotic (George et al., 2006).
Therefore, the best way to protect individuals at high risk is
through the development of efficacious vaccines which are able
to evoke sterilizing immunity or delay the onset of bacteremia
and septic shock, to extend the window of opportunity for antibi-
otic treatment and still be of significant clinical benefit. To date,
there is very little information available on the seroepidemiol-
ogy of melioidosis in the endemic community (Finkelstein et al.,
2000;Wuthiekanun et al., 2008). A seroepidemiological study per-
formed in Khon Khean, Thailand, demonstrated that although a
majority of the children were seropositive toward B. pseudomallei,
none of them expressed symptoms of melioidosis, indicating the
latency of B. pseudomallei in human host (Kanaphun et al., 1993).
Additionally, a study conducted in Malaysia revealed seropositiv-
ity among melioidosis patients and healthy individuals (Vadivelu
et al., 1995). With this existing herd immunity in endemic areas,
the development of vaccines would be beneficial.
HURDLES IN DEVELOPMENT OF Burkholderia VACCINES
At present, no efficacious vaccines are available to prevent infec-
tions caused by Burkholderia spp. as none are able to achieve
sterilizing immunity (Elkins et al., 2004). Despite reports on the
ability of several Burkholderia vaccines to confer some immuno-
protection, none of the vaccines have reached the clinical trial
state indicating that there are, major difficulties that exist in
the development of safe vaccines against Burkholderia infections
(Elkins et al., 2004).
An important strategy to consider is the ability of the host
to generate a specific immune response in the respiratory tract
essentially so that it could prevent the early steps of coloniza-
tion and infection by these bacteria, thus preventing or reducing
lung damage due to inflammation during subsequent infec-
tions. Another dilemma in this scenario is, unlike infectious
model agents, like Escherichia coli or Salmonella typhimurium, the
pathogenesis of Burkholderia spp. and the specific mechanisms
by which these bacteria subvert the host defense mechanisms
are not well understood. Clinical manifestations of melioido-
sis are also varied widely from asymptomatic seroconversion,
acute manifestation of septicemia, localized abscesses, dissem-
inated infections which lead to concomitant pneumonia and
multiple organ abscesses to quiescent latent infection. However,
to date, the mechanisms and involvement of altered metabolism
in latency is still unclear. Whether the clinical manifestations of
the patient were determined by the host, pathogen, or the out-
come of the interactions of both parties needs to be clarified (Gan,
2005).
To further compound this issue, Burkholderia spp. are fac-
ultative intracellular pathogens that are able to invade non-
phagocytic cells which leads to the evasion of the humoral
immune responses (Lazar Adler et al., 2009). Therefore, elim-
ination of intracellular Burkholderia spp. is highly reliant on
the cell-mediated immune responses. In addition, clearance of
B. pseudomallei in patients has also been shown to be ineffective
despite the presence of immunoglobulin G1 (IgG1) response, sug-
gesting the stimulation of Th2 immune response (Puthucheary,
2009). This complicated host–pathogen interaction confers major
challenges in the rational design of effective and safe vaccines
for use.
Vaccine trial studies in animals have demonstrated develop-
ment of immunity against Burkholderia spp. in the vaccinated
animals. Despite developing immunity in animal vaccine stud-
ies, postmortem results have indicated the presence of bacteria
in multi organ systems of the vaccinated animals indicating that
the sterilizing immunity which is the ultimate goal of vaccine
was unable to be achieved in most cases. Another proviso to
these studies was the finding that experimental vaccine candi-
dates available were only efficient in protecting against acute
Burkholderia infections but not against chronic Burkholderia
infections (Patel et al., 2011).
With these issues in the background and the lack of knowledge
on the host–pathogen interactions being themost prominent hin-
drance in the development of vaccine against Burkholderia spp., to
date no effective vaccines have been made available.
ANIMAL MODELS FOR Burkholderia VACCINES
DEVELOPMENT
In order to study the efficacy of any vaccine, a suitable infection
model is a pre-requisite. To date, although different animal mod-
els have been used for Burkholderia spp. infection studies, among
themost extensively developed and describedmodels available are
those used for studies on B. pseudomallei. Themodels widely used
for B. pseudomallei experimentation include the rodent models,
especially the inbred mice strains, BALB/c and C57BL/6, and the
Syrian golden hamster (Brett et al., 1997; Fritz et al., 1999; Warawa
and Woods, 2005).
The use of Syrian golden hamster in Burkholderia infection
and vaccines development studies are limited since it is not as
well characterized as the BALB/c and C57BL/6 model. The Syrian
golden hamster model is also highly susceptible to Burkholderia
infection and unable to mimic human infection (Bondi and
Goldberg, 2008).
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In melioidosis, it has been demonstrated clinically that release
of proinflammatory cytokines in human leads to the pathological
changes in acute melioidosis patients. The levels of proinflamma-
tory cytokines also correlated with severity of acute melioidosis in
patients (Wiersinga and Van Der Poll, 2009). Similarly, in BALB/c
mice, a surge of proinflammatory cytokines levels peaking at
24–48 h after infection was observed. In addition, there was also
poor recruitment of lymphocytes and macrophages to the infec-
tion site leading to inefficient clearance of B. pseudomallei result-
ing in a failure to contain the bacteria. This phenomenon, coupled
with the surge of proinflammatory cytokines eventually led to
extensive tissue necrosis with a high bacterial load (Lazar Adler
et al., 2009). Therefore, B. pseudomallei infected-BALB/c mice
highly resemble acute humanmelioidosis and it is a relatively suit-
able animal model to study the efficacy of a vaccine against acute
Burkholderia infection (Macdonald and Speert, 2007).
In contrast to the BALB/c mice, the C57BL/6 exhibit lower
secretion of proinflammatory cytokines levels which peaks at a
later time (approximately 48–72 h). Higher rate of neutrophils
and macrophages infiltration to the infection site have been
observed to control the B. pseudomallei efficiently to prevent
unrestricted spread of the bacteria in C57BL/6 (Lazar Adler
et al., 2009). Lower bacterial loads were recovered from organs
of infected C57BL/6 mice. These might indicate that C57BL/6 is
more resistant to B. pseudomallei infection compared to BALB/c
mice and as such, is suitable to be used as a chronic model for
B. pseudomallei infection studies (Macdonald and Speert, 2007).
Long-term latency and recrudescence is one of the important
features in human melioidosis which is not presented by BALB/c
and C57BL/6 mice upon B. pseudomallei infection. Therefore,
there is still no appropriate animal model in the study of B. pseu-
domallei latency in host. According to Titball et al. (2008), the
TO outbred mice are highly resistant to B. pseudomallei infection
and they have suggested that the TO outbred mice might be an
important model to dissect the mechanisms of long-term latency
of B. pseudomallei in the host. However, the use of this mouse
model has not been widely adopted.
Thus, to date there is no definite suitable rodent models for
research in vaccine development especially for human melioido-
sis. Since melioidosis demonstrates highly varied symptomatic
outcome, none of the rodent models available are able to present
all stages (i.e., acute, chronic, and latency states) of humanmelioi-
dosis. Therefore, the lack of suitable testingmodels pose themajor
limitation in the study of the effectiveness of vaccine models
against Burkholderia infections.
CURRENT STRATEGIES AND DEVELOPMENT OF
Burkholderia VACCINES
Available in the literature are substantial report on development
of vaccines for B. pseudomallei but far less for B. mallei and
B. cepacia. It has been indicated that some of the vaccines that
have been developed for melioidosis do offer cross-protection to
B. mallei and B. cepacia infections (Sarkar-Tyson et al., 2009).
SUBUNIT VACCINES
Subunit vaccine took advantage of the ability of many different
virulence factors of a pathogen to evoke immune responses in
order to provide protection to the pathogen. However, prepara-
tion of these subunits as a vaccine require large-scale cultures
of the pathogenic organism which can be hazardous due to
production of aerosols and presence of large amounts of live
bacteria and therefore, require extremely tight stringent safety
procedures during production. This therefore led to the devel-
opment of recombinant subunits as alternatives that could be
delivered as purified subunit immunogens or DNA encoding the
immunogens (Liljeqvist and Stahl, 1999).
Burkholderia pseudomallei
Several of the recombinant subunit candidates have been identi-
fied to protect against B. pseudomallei infection. Themost notable
candidate being LolC, an outer membrane protein (OMP) of
B. pseudomallei associated with ATP-binding cassette system
(Yakushi et al., 2000). Harland et al. (2007) demonstrated that
BALB/c mice immunized with recombinant LolC protein exhib-
ited survivability rate of 80% after six weeks post-infection.
Similarly, recombinant LolC protein administered with adjuvant
also provided significant protection against challenge using a het-
erologous strain of B. pseudomallei containing the LolC gene.
The immunization using LolC with immune-stimulating com-
plex and CpG oligodeoxynucleotide (ODN) stimulated Th-1 type
immune response. In the same study, recombinant PotF protein
protected 50% of the challenged mice. Immunization with both
proteins elicits a Th-1 type immune response in mice which is
important in cell-mediated immune response. However, it is not
clear whether sterile immunity was achieved in the surviving mice
(Table 1).
Burtnick et al. (2011) identified another subunit vaccine can-
didate, Hcp proteins (components of the newly discovered Type 6
Secretion System), which is able to achieve a similar survivability
rate as the recombinant LolC protein in the BALB/cmouse model.
Six recombinant Hcp proteins (Hcp1–Hcp6) were tested for their
ability to confer protection against intraperitoneal B. pseudo-
mallei challenge and vaccination using the recombinant Hcp2
protein was found to exhibit a survival rate of 80% at 42 days
post-infection (Burtnick et al., 2011). However, vaccination using
Hcp1, Hcp3, andHcp6 only protected 50% of the challengedmice
after 42 days of infection while none of the mice immunized with
Hcp4 and Hcp5 survived the challenge. It is noteworthy to men-
tion that no bacteria were found in the spleen of the survivors
immunized with Hcp1 and Hcp6 while bacteria were recov-
ered from Hcp2-immunized survivors suggesting that sterilizing
immunity is possible (Table 1).
Other virulence factors of B. pseudomallei such as the surface
polysaccharides have also been investigated as subunit vaccines
especially two of the most well characterized B. pseudomallei
surface polysaccharides i.e., the capsular polysaccharide (type I
O-PS) and lipopolysaccharide (LPS) (type II O-PS) (Deshazer
et al., 1998; Reckseidler et al., 2001; Nelson et al., 2004). Passive
immunizations with antibodies to the LPS or capsular polysac-
charide were demonstrated to reduce lethality of infection in
mice and diabetic rats suggesting that these polysaccharides are
of immunological importance (Bryan et al., 1994; Jones et al.,
2002). Nelson et al. (2004) suggested the LPS or capsular polysac-
charide as potential vaccine candidates for B. pseudomallei as
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vaccination of the BALB/c mice with these polysaccharides fol-
lowed by an intraperitoneal route of challenge increased the mean
time to death (MTTD) compared to the unvaccinated control
which exhibited a MTTD of 2.6 days, with 100%mortality occur-
ring by day 11. Lipolysaccharide provided the highest level of
protection with a MTTD of 17.6 days and 50% survival at day 35
followed by mice immunized with capsular polysaccharide with a
MTTD of 10.5 days and 100%mortality by day 28. Contrastingly,
when the mice were challenged using an aerosol route, a slight
increase of MTTD was observed as compared with the unvac-
cinated controls. Additionally, passive transfer of antibody from
the immunized mice into the naïve mice also provided protection
against subsequent challenges using B. pseudomallei.
In another study, since the LPS O-antigen of B. thailanden-
sis and B. pseudomallei share a high similarity of >90%, the
LPS O-antigen of B. thailandensis was used as a potential vac-
cine candidate. Ngugi et al. (2010) demonstrated that vaccination
using both B. thailandensis LPS and B. pseudomallei LPS induced
comparable levels of partial of protection against B. pseudomallei
infections. Vaccination with B. thailandensis LPS exhibited 50%
survival of the mice at day 35 post-challenge with a MTTD of
32.8 days whereas vaccination using B. pseudomallei LPS exhib-
ited 66% survival of mice with a MTTD of 31.5 days. The ability
of using the LPS of B. thailandensis, the avirulent counterpart of
B. pseudomallei to provide comparable levels of partial protec-
tion against melioidosis is applauded since extraction of LPS from
B. thailandensis which is a BSL-2 pathogen pose lower costs and
more importantly reduced safety risk compared to the extraction
from B. pseudomallei.
Other subunit vaccine candidates comprising recombinant
flagellin antigens, recombinant OMP, outer membrane vesicles
(OMV) and peptide mimotypes have also been tested with var-
ious degree of protection against Burkholderia spp. infection
(Chen et al., 2006b; Legutki et al., 2007; Hara et al., 2009; Su et al.,
2010; Nieves et al., 2011a). However, no sterile immunity was
reported using all these candidates (Table 1). Subunit vaccines
should still be considered as potential vaccine candidates as many
immunogenic virulence factors of Burkholderia species have not
yet been evaluated for their protective effects (Mariappan et al.,
2010; Vellasamy et al., 2011).
Burkholderia mallei
A recent study byWhitlock et al. (2011) achieved 37.5–87.5% sur-
vival rate upon challenge by B. mallei when mice are immunized
with recombinant antigen proteins. These protective antigen pro-
teins were identified by expression library immunization. This
method might serves as a model for mass screening of potential
vaccine candidate.
Burkholderia cepacia
Virulence factors such as proteases, LPS core antigen, flagella anti-
gens, exopolysaccharides, and elastase have been considered as
targets for development of vaccine against B. cepacia infections.
However, none of these antigens are thought to be protective
(Doring and Hoiby, 1983; Fujita et al., 1990; Nelson et al.,
1993). Recently, a carbohydrate-based potential vaccine has been
described which is a trisaccharide based on the repeating unit
of a polysaccharide in the LPS of a clinical isolate of B. cepacia.
However, coupling of trisaccharide or unprotected trisaccharide
with a T cell epitope has yet to be developed (Faure et al., 2007).
Using a murine model of chronic pulmonary infection with
B. cepacia, Bertot et al. (2007) demonstrated that intranasal
immunization with OMP can induce specific mucosal immune
responses in the respiratory tract, which in turn enhances the
clearance of B. cepacia and minimize lung inflammatory damage
after bacterial challenge. In addition, they have also suggested that
the OMP may provide cross-protection against other Bcc mem-
bers. Immunoglobulin G antibodies to B. cepaciaOMP have been
detected in sera of CF patients colonized with both B. cepacia and
P. aeruginosa, suggesting cross-reactivity between the OMPs of
these organisms (Aronoff et al., 1991).
In addition, Makidon et al. (2010) confirmed the findings of
Bertot et al. (2007) and demonstrated significant response to
the 17 kDa OmpA lipoprotein. In their study, it was found that
immunized mice were protected against pulmonary colonization
with B. cepacia and they have also identified a new immun-
odominant epitope, a 17 kDa OmpA-like protein which is highly
conserved between Burkholderia and Ralstonia spp. In addition,
serum analysis showed robust IgG and mucosal secretory IgA
immune responses in vaccinated versus control mice and this
suggest that the antibodies had cross-neutralizing activity against
Bcc. Makidon et al. (2010) have also suggested that the 17 kDa
OmpA-like protein shows potential for future vaccine develop-
ment and provides a rational basis for vaccines using recombinant
OMP mixed with nano-emulsion as an adjuvant.
More recently, 18 immunogenic proteins from B. cepacia cul-
ture supernatant that reacted with mice antibodies raised to
B. cepacia inactivated whole bacteria, OMP, and culture filtrate
antigen were suggested to be potential molecules as a diagnos-
tic marker or putative candidates for development of vaccine and
therapeutic intervention against B. cepacia infections (Mariappan
et al., 2010). Additionally, secretory proteins of B. cepacia have
been suggested as possible targets for the development of new
strategies to control B. cepacia infection using agents that can
block their release (Mariappan et al., 2011).
Metalloproteases are also being considered as potential effec-
tive candidates for vaccine development (Corbett et al., 2003).
Furthermore, it was demonstrated that immunizations of mice
using a conserved zinc metalloprotease peptide decreased the
severity of B. cepacia infection and the lung damage was reduced
by 50% on challenge with a B. cepacia strain after immuniza-
tion with this peptide (Corbett et al., 2003). Additionally, BLAST
analysis demonstrated that metalloprotease shared a 96% and
above homology with the metalloprotease of B. pseudomallei
K96243. Therefore, this protein has been suggested to be used to
cover immunization for both B. cepacia and B. pseudomallei to
cross-protect (Mariappan et al., 2010).
LIVE ATTENUATEDVACCINES
Live vaccines have been widely used for vaccination against infec-
tious diseases, such as tuberculosis, cholera, mumps, andmeasles.
Previously, live attenuated vaccines were developed from attenu-
ated strains which have undergone passages in laboratory con-
ditions or immunologically related species/microorganism that
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does not use human as the target host. Live attenuated vac-
cines are able to replicate and are recognized as foreign by
human body without causing any pathological or lethal effects.
Empirical approaches used for live vaccines development are
time-consuming and the basis of attenuation is usually unde-
fined. The advancement of modern DNA recombinant technol-
ogy enables researchers to specifically inactivate essential gene(s)
involved in pathogenesis, which leads to the development of
well-defined attenuated live vaccines (Clare and Dougan, 2004).
Live attenuated vaccines are considered the most ideal vaccine
with great advantage due to the ability to elicit wide range of
immune responses. Burkholderia pathogens are cytosolic intra-
cellular bacteria whereby the antigenic proteins present in the
cytosol after endosomal escape will be processed by the protea-
some in the endogenous pathway and presented to CD8+ T cells
by class I major histocompatibility complex (MHC). In contrast,
inactivated vaccines are generally unable to induce CD8+ cyto-
toxic T cell immunity, which is essential in clearing intracellular
pathogens (Seder andHill, 2000). Live attenuated vaccines require
lesser or even only a dose of vaccination for long lasting immune
protection and without the use of adjuvant.
Burkholderia pseudomallei
To date, genes involving capsular polysaccharide synthesis and
amino acid synthesis pathways (for example, shikimic pathway,
and branch chain amino acids synthesis) are the main targets
for creating attenuated variant. Acapsular mutant of B. pseudo-
mallei (strain 1E10) created by Atkins et al. (2002a) showed no
immunization protective effect toward BALB/c mice challenged
by B. pseudomallei strain 576. The gmhA and wcbJ mutant strains
which are defective in capsular polysaccharide synthesis were
used to immunize BALB/c mice. The immunized mice were par-
tially protected from B. pseudomallei challenge; however, sterile
immunity was not achieved.
Several other genes involved in essential amino synthesis
pathway have also been knocked-out and exhibited attenuated
virulence. The B. pseudomallei strain 2D2 with defective ace-
tolactate synthase (ilvI) gene identified from a mutant library
are a branch amino acid auxotroph. Mice vaccinated with 2D2
survived longer compared to naïve mice when challenged with
B. pseudomallei 576 and BRI but not protected toward Francisella
tularensis challenge (Atkins et al., 2002b). In another study per-
formed by Haque and his team (2006) using B. pseudomallei
2D2 as the vaccine model have demonstrated that vaccinated
mice elicited CD4+ immune reaction as a protective mechanism
against B. pseudomallei infections. With the same vaccination
model, intranasal route of vaccination was shown to confer bet-
ter protection toward pulmonary B. pseudomallei infection which
was associated with higher production of interferon-γ (IFNγ)
compared to intraperitoneal administration (Easton et al., 2011).
The same study also demonstrated that vaccination incorpo-
rated with intranasal CpG ODN treatment extended survival
ability of vaccinated mice, highly reduced lung bacterial load and
delayed onset of bacterial sepsis after challenge. Similarly, ilvI
gene, phosphoserine aminotransferase (serC) (Rodrigues et al.,
2006), dehydroquinate synthase (aroB) (Cuccui et al., 2007), cho-
rismate synthase (aroC) (Srilunchang et al., 2009), and aspartate
semialdehyde dehydrogenase (asd) (Norris et al., 2011a) genes
have also been utilized as gene targets to develop amino acid
auxotrophs for vaccination studies in melioidosis (Table 2).
The type 3 secretion system cluster 3 (TTSS3) (Stevens et al.,
2004) encodes important virulence factors which are highly
involved in B. pseudomallei pathogenesis (Lazar Adler et al.,
2009). Based on this, a mutant defect in the translocator protein
gene, bipD, was constructed by Stevens et al. (2004) for BALB/c
mice immunization and the immunized mice exhibited partial
protection against B. pseudomallei infections. Besides the genes
involved in amino acid synthesis, polysaccharide synthesis, and
T3SS, genes involved in purine synthesis pathway are also can-
didates for construction of live attenuated vaccines. The purN
defective mutant strains were used for immunization in the study
performed by Breitbach et al. (2008). Protection against B. pseu-
domallei challenge was demonstrated in immunized BALB/c mice
(Breitbach et al., 2008) (Table 2). Another mutant strain created
in the same study (purM-knock out strain) demonstrated dosage-
dependent protection whereby mice immunized with higher
dosage of purM mutant exhibited better protection than that of
lower dosage (Table 2).
Interestingly, B. pseudomallei strain CL04 (isolated from a
chronic melioidosis patient) (Ulett et al., 2005) and NTCC 13179
(Barnes and Ketheesan, 2007) exhibited natural attenuated viru-
lence and protection properties when immunized BALB/c mice
were challenged with virulent B. pseudomallei strains (Table 2).
However, CL04 and NTCC 13179 are wild type B. pseudomallei
strains isolated frommelioidosis patients and these strains are not
suitable to be used as the live attenuated vaccine candidates.
Burkholderia mallei
Similar to B. pseudomallei, the mutant strain 1E10, an acapsu-
lar mutant of B. mallei (strain DD3008) exhibited no vaccina-
tion protection toward challenge against B. mallei ATCC 23344
(Deshazer et al., 2001). This might be due to the development
of IgG1 (Th2-like immunoglobulin) antibody response in vac-
cinated mice (Ulrich et al., 2005). B. mallei knockout strain of
ilvI (strain ILV1) was also constructed in order to develop vac-
cines against B. mallei and to study the effect of vaccination on
glanders. As reported by Ulrich and others (2005), B. mallei ILV1-
vaccinated mice developed IgG2 (Th1-like immunoglobulin)
antibody response which conferred resistance toward B. mallei
infection. However, ILV1 vaccination does not confer sterile
immunity and the vaccinated mice developed splenomegaly fol-
lowing challenge with live bacteria (Table 3). Apart from the
ilvI gene, gene knockouts for capsule production (wcbB) and
carboxyl-terminal protease-encoded gene (ctpA) also demon-
strated attenuated virulence of B. mallei. Administration of the
wcbB and ctpA knockout strains conferred protection against wild
type B. mallei in vaccinated animal models (Table 3).
Despite accumulating data on live attenuated vaccines against
B. pseudomallei and B. mallei, the analysis is rather complicated
due to the different immunization protocols, wild type chal-
lenge dosages, route of administration, and animal model used.
Therefore, the results are not comparable in order to determine
the most suitable live attenuated vaccine candidate for use as
potential Burkholderia vaccines (Sarkar-Tyson and Titball, 2010).
Frontiers in Cellular and Infection Microbiology www.frontiersin.org February 2013 | Volume 3 | Article 5 | 7
Choh et al. Burkholderia vaccines
Ta
b
le
2
|S
u
m
m
ar
y
o
f
liv
e
at
te
n
u
at
ed
va
cc
in
e
d
ev
el
o
p
m
en
t
ag
ai
n
st
B
.p
se
u
d
o
m
al
le
i.
R
ef
er
en
ce
s
M
u
ta
te
d
ge
n
e
Im
m
u
n
iz
at
io
n
C
h
al
le
n
ge
Pe
rc
en
ta
ge
su
rv
iv
ed
D
o
sa
ge
D
u
ra
ti
o
n
R
o
u
te
A
n
im
al
m
o
d
el
S
tr
ai
n
D
o
sa
ge
R
o
u
te
A
tk
in
s
et
al
.
(2
00
2a
)
M
an
no
sy
ltr
an
sf
er
as
e
(1
E
10
st
ra
in
)
10
6
5
w
ee
ks
In
tr
ap
er
ito
ne
al
B
A
LB
/c
57
6
10
4
In
tr
av
en
ou
s
0%
at
da
y
18
A
tk
in
s
et
al
.
(2
00
2b
)
A
ce
to
la
ct
at
e
sy
nt
ha
se
(iv
lI)
(2
D
2
st
ra
in
)
10
6
5
w
ee
ks
In
tr
ap
er
ito
ne
al
B
A
LB
/c
57
6
10
6
In
tr
ap
er
ito
ne
al
80
%
at
da
y
35
S
te
ve
ns
et
al
.
(2
00
4)
Ty
pe
III
se
cr
et
io
n
sy
st
em
cl
us
te
r
3
tr
an
sl
oc
at
or
pr
ot
ei
n
(b
ip
D
)
10
4
5
w
ee
ks
In
tr
ap
er
ito
ne
al
B
A
LB
/c
57
6
10
4
In
tr
ap
er
ito
ne
al
60
%
at
da
y
70
U
le
tt
et
al
.(
20
05
)
W
ild
ty
pe
(C
L0
4
st
ra
in
)
8.
5
×
10
3
2
w
ee
ks
U
nk
no
w
n
B
A
LB
/c
N
C
TC
13
17
8
7.
2
×
10
2
U
nk
no
w
n
40
%
at
da
y
14
Im
m
un
iz
at
io
n:
1
w
ee
k
B
oo
st
er
:1
w
ee
k
10
0%
at
da
y
14
H
aq
ue
et
al
.
(2
00
6)
A
ce
to
la
ct
at
e
sy
nt
ha
se
(iv
lI)
(2
D
2
st
ra
in
)
10
6
5
w
ee
ks
In
tr
ap
er
ito
ne
al
B
A
LB
/c
57
6
10
6
In
tr
ap
er
ito
ne
al
40
%
at
da
y
75
R
od
rig
ue
s
et
al
.
(2
00
6)
P
ho
sp
ho
se
rin
e
am
in
ot
ra
ns
fe
ra
se
(s
er
C
)(
4D
6
st
ra
in
)
10
5
5
w
ee
ks
In
tr
ap
er
ito
ne
al
B
A
LB
/c
K
96
24
3
an
d
57
6
10
4
In
tr
ap
er
ito
ne
al
80
%
at
da
y
25
B
ar
ne
s
an
d
Ke
th
ee
sa
n
(2
00
7)
W
ild
ty
pe
(N
TC
C
13
17
9)
29
0
Im
m
un
iz
at
io
n:
10
da
ys
Fi
rs
t
bo
os
te
r:
20
da
ys
S
ec
on
d
bo
os
te
r:
15
da
ys
S
ub
cu
ta
ne
ou
s
B
A
LB
/c
N
TC
C
13
17
8
20
In
tr
av
en
ou
s
81
.8
0%
at
da
y
40
C
uc
cu
ie
t
al
.
(2
00
7)
D
eh
yd
ro
qu
in
at
e
sy
nt
ha
se
(a
ro
B
)
(1
3B
11
st
ra
in
)
10
5
5
w
ee
ks
In
tr
an
as
al
B
A
LB
/c
K
96
24
3
10
3
In
tr
an
as
al
0%
at
da
y
8
10
6
0%
at
da
y
8
B
re
itb
ac
h
et
al
.
(2
00
8)
pu
rN
10
5
3
w
ee
ks
In
tr
ap
er
ito
ne
al
B
A
LB
/c
E
8
10
5
In
tr
ap
er
ito
ne
al
10
0%
at
da
y
30
pu
rM
10
0%
at
da
y
28
S
ril
un
ch
an
g
et
al
.
(2
00
9)
C
ho
ris
m
at
e
sy
nt
ha
se
(a
ro
C
)
3
×
10
7
Im
m
un
iz
at
io
n:
1
w
ee
k
B
oo
st
er
:1
w
ee
k
In
tr
ap
er
ito
ne
al
B
A
LB
/c
A
2
5
×
10
2
In
tr
ap
er
ito
ne
al
0
5
×
10
3
0
5
×
10
4
0
5
×
10
8
C
57
B
L/
6
6
×
10
3
80
%
at
da
y
15
0
6
×
10
4
60
%
at
da
y
15
0
6
×
10
5
20
%
at
da
y
15
0
(C
on
tin
ue
d)
Frontiers in Cellular and Infection Microbiology www.frontiersin.org February 2013 | Volume 3 | Article 5 | 8
Choh et al. Burkholderia vaccines
Ta
b
le
2
|C
o
n
ti
n
u
ed
R
ef
er
en
ce
s
M
u
ta
te
d
ge
n
e
Im
m
u
n
iz
at
io
n
C
h
al
le
n
ge
Pe
rc
en
ta
ge
su
rv
iv
ed
D
o
sa
ge
D
u
ra
ti
o
n
R
o
u
te
A
n
im
al
m
o
d
el
S
tr
ai
n
D
o
sa
ge
R
o
u
te
N
or
ris
et
al
.
(2
01
1b
)
A
sp
ar
ta
te
se
m
ia
ld
eh
yd
e
de
hy
dr
og
en
as
e
(a
sd
)
10
7
Im
m
un
iz
at
io
n:
3
w
ee
ks
B
oo
st
er
:2
w
ee
ks
In
tr
an
as
al
B
A
LB
/c
10
26
b
4
×
10
3
In
tr
an
as
al
20
%
at
da
y
50
E
as
to
n
et
al
.
(2
01
1)
A
ce
to
la
ct
at
e
sy
nt
ha
se
(iv
lI)
(2
D
2
st
ra
in
)c
om
bi
ni
ng
w
ith
C
pG
10
5
5
w
ee
ks
In
tr
an
as
al
B
A
LB
/c
57
6
3
×
10
2
In
tr
an
as
al
un
kn
ow
n
C
uc
cu
ie
t
al
.
(2
01
2)
S
ed
ah
ep
tu
lo
se
-7
-p
ho
sp
ha
te
is
om
er
as
e
(g
m
hA
)
10
3
5
w
ee
ks
In
tr
an
as
al
B
A
LB
/c
K
96
24
3
10
3
In
tr
an
as
al
0%
at
da
y
35
R
ed
uc
ta
se
(w
cb
J)
33
%
at
da
y
35
KILLED WHOLE CELL VACCINES
Killed whole cell vaccines are non-living pathogens which remain
immunogenic for host immune system to recognize as “for-
eign.” These vaccines have been widely used for the prevention of
anthrax, Q fever, and whooping cough (Ada, 2001). This type of
vaccine is known to induce a narrow range of immune responses
due to the inability to replicate in the host. On the other hand,
the inability to replicate is also a major advantage for the killed
whole cell vaccines; making them an extremely safe prophylactic
stimulation of the immune system and as such suitable for vacci-
nations on immunocompromised individuals. These vaccines are
also good candidates for inducing humoral immunity to produce
neutralizing antibodies. It is generally known that killed whole
cell vaccines do not stimulate strong cellular-mediated immunity
due to the fact that the antigens are not processed by an endoge-
nous pathway and presented to the T cells by class I MHC. Hence,
multiple doses of vaccination and adjuvants are required for
long lasting protection (Ada, 2003). Experimental testing of the
potency of kill whole cell vaccines in Burkholderia spp. has been
investigated employing various animal models, administration
and challenge routes, inactivation protocols, and adjuvants.
B. pseudomallei
Inactivated Burkholderia pathogens confer different degrees of
protections toward B. pseudomallei and B. mallei infections.
B. pseudomallei, B. mallei, and B. thailandensis are phyloge-
netically closely related and hence, cross protections are highly
possible. Study conducted by Sarkar-Tyson et al. (2009) has
demonstrated that immunization by heat-inactivated B. mallei
and B. thailandensis conferred protection toward B. pseudomallei
infections. In fact, BALB/c mice immunized by heat-inactivated
B. malleiATCC 23344 exhibited better protection (i.e., higher sur-
vival percentage and longerMTTD) against B. pseudomallei strain
K96243 infection compared to mice immunized by heat-killed
B. pseudomallei strain K96243 and 576. Barnes and Ketheesan
(2007) also, demonstrated that heat-killed B. pseudomallei immu-
nization via subcutaneous route does not protect immunized
mice from subsequent challenge but heat-killed B. pseudomallei
co-injected with culture filtrate antigen significantly increase the
protection toward subsequent challenge (Table 4).
Other studies have demonstrated that the presence of cap-
sular polysaccharide and LPS were able to affect the immuno-
genicity of heat-inactivated B. pseudomallei (Sarkar-Tyson et al.,
2007). Heat-killed capsular polysaccharide mutant (wcbH knock-
out) and LPS O antigen mutants (wbiA knockout) demonstrated
higher vaccination protection against B. pseudomallei (70% and
80% after day 35, respectively) in comparison to mice vacci-
nated with heat-killed putative type III O-polysaccharide mutant
(BPSS0421 knockout) and putative type IV O-polysaccharide
mutants (BPSS1833 knockout) in the study of Sarkar-Tyson and
collaborators (2007) (Table 4). The authors have postulated that
depletion of capsular polysaccharide and LPS might leads to
the exposure of hidden immunogens or upregulation of the
less abundant surface polysaccharides. The use of cationic lipo-
somes complexed with non-coding plasmid DNA as mucosal
adjuvant with heat-killed B. pseudomallei has also been found
to increase the survival rate of challenged BALB/c mice to 100%
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(after day 40) compared to BALB/c only immunized with heat-
killed B. pseudomallei (Henderson et al., 2011) (Table 4).
Dendritic cells are strong professional antigen presenting cells
(APC) which induce strong adaptive immunity, especially T cells-
based immunity. Therefore, delivering antigen-primed dendritic
cells into human is a potential method to induce vaccinated
protection. Thus, pulsing of inactivated B. pseudomallei into den-
dritic cells was performed and reported. Mice immunized by
heat-killed B. pseudomallei pulsed dendritic cells demonstrated
significant stronger cell-mediated immune responses compared
to mice immunized by heat-killed B. pseudomallei. The addition
of CpG ODN with heat-killed B. pseudomallei during priming
of dendritic cells or as adjuvant demonstrated increase in the
secretion of IFNγ (indicating the stimulation of Th1 immune
responses) and anti-B. pseudomallei antibody production (Healey
et al., 2005; Elvin et al., 2006) (Table 4).
Burkholderia mallei
Amemiya et al. (2002), demonstrated that BALB/c mice immu-
nized by heat-inactivated B. mallei strain ATCC 23344 with
Alhydrogel as adjuvant showed mixed Th1- and Th2-like cytokine
responses in spleenocytes and Th2-like IgG responses. However,
these vaccinated mice were not protected from the B. mallei chal-
lenge. This study eventually led to the investigation of the protec-
tive effects conferred by co-administration of interleukin (IL) 12
with heat-killed B. mallei and Alhydrogel adjuvant. Incorporation
of IL12 increased the secretion of IFNγ and IL10 while at the
same time increasing the production of anti-B. mallei IgG2.
These collectively indicate that the Th1 response was stimulated
in BALB/c mice challenged with live B. mallei. Th1 immune
response elicited after inclusion of IL12 in the vaccination regime
has conferred partial protection against B. mallei challenged via
intraperitoneal route (Amemiya et al., 2006). However, stud-
ies reported by Whitlock and others (2008) demonstrated that
sterilizing immunity was not achieved in immunized BALB/c.
Interestingly, the greatest protection against B. mallei was not
conferred by heat-inactivated bacteria from the same species but
from a closely related species as demonstrated by Sarkar-Tyson
et al. (2009). They observed higher resistance exhibited by BALB/c
mice immunized with heat-inactivated B. pseudomallei K96243
compared to the BALB/c mice immunized with heat-inactivated
B. mallei ATCC 23344 when challenged with B. mallei ATCC
23344 (Table 5).
DNA VACCINES
Immunization using DNA is used to efficiently stimulate humoral
and cellular immune responses to protein antigens. When a
genetic material is directly injected into the host, a small
amount of the host’s cells will express the related gene prod-
ucts. This inappropriate gene expression within the host has
important immunological consequences, resulting in the specific
immune activation of the host against the gene delivered antigen
(Koprowski and Weiner, 1998).
Currently the only DNA vaccine developed against any
Burkholderia spp. utilizes the fliC gene of B. pseudomallei. Chen
et al. (2006b) demonstrated that mice vaccinated with plasmid
DNA using mammalian expression vector pcDNA3/fliC gene
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survived better than mice vaccinated with recombinant FliC
protein (83% vs. 50%). Plasmid DNA encoding the flagellin
gene was able to generate high levels of specific antibodies in
which upregulation of IFN-γ and increase in the IgG2a/IgG1
ratio was observed. However, generally the DNA vaccines were
reported to induce weaker immune response in humans (Liu,
2011). It was demonstrated that immunization of mice with
priming of immuno-stimulatory CpG motifs and pcDNA3/fliC
further enhances the survivability to 93.3% when challenged with
B. pseudomallei (Chen et al., 2006a).
POTENTIAL VACCINE APPROACHES
When BALB/c mice were immunized with heat-inactivated
B. thailandensis significant delay in the MTTD post-challenged
with B. pseudomallei compared to non-immunized BALB/c mice
were observed. Therefore, B. thailandensis may be considered a
potential vaccine candidate, following genetic modification in
order to express the immunogenic proteins from B. pseudomallei
and B. mallei. In addition, Iliukhin et al. (2004), demonstrated
that immunized animal models conferred resistance to B. pseu-
domallei and B. mallei following subcutaneous administration of
live attenuated F. tularensis. It was suggested that F. tularensis
may also be considered as a potential candidate for Burkholderia
vaccines development since it is also a cytoplasmic facultative
intracellular bacteria, similar to Burkholderia pathogens.
To date, development of live attenuated vaccines for
Burkholderia spp. has only exploited the knockout of one gene at
a time using techniques such as genetic alterations of bacteria via
transformation, conjugation, or transduction. Therefore, rever-
sion from attenuated strain to wild-type strain can occur in the
environment and hence a major concern in the use of live atten-
uated bacteria as vaccine candidates. Two or more independent
site-specific knockout should be considered as demonstrated in
S. typhi strain CVD 908-htrA and Shigella flexneri strain CVD
1207. This approach needs to be treated with caution as it may
pose the risk of over attenuation leading to a reduced immuno-
genicity of the attenuated vaccine as demonstrated for S. typhi
strain 541Ty (Clare and Dougan, 2004).
It is well-known that heat and chemical treatment on
pathogens for killed whole cell vaccines poses risk of affect-
ing the immunogenicity. An alternative approach to inactivate
Gram-negative pathogens like Burkholderia spp. without affect-
ing the immunogen epitopes is the creation of a bacterial ghost
by employing PhiX174 E gene lytic mechanism. The lysis E gene
encodes a hydrophobic protein which produces transmembrane
channels and releases the cytoplasmic content of the pathogen.
This leaves the empty bacterial cell envelop which retains the
immunogenicity and is able to stimulate APCs for major his-
tocompatibility presentation (Haslberger et al., 2000; Talebkhan
et al., 2010). This technique has been exploited in a variety
of Gram-negative bacterial vaccine development (Szostak et al.,
1996). Since there are a number of lytic Burkholderia bacterio-
phages that have been reported, exploiting the next generation
sequencing and bioinformatics techniques, a more sophisticated
lysis system could be employed for the creation of bacterial ghost
of Burkholderia pathogens, as tools for killed whole cell vaccine
development.
COST EFFECTIVENESS AND EFFICACY OF A Burkholderia
VACCINE
In a recent paper, Peacock et al. (2012) emphasized the impor-
tance of cost-effectiveness of vaccines against B. pseudomallei. The
study demonstrated the need to produce cost savings or at least
potential savings depending on the level of efficacy of the vaccine,
vaccination coverage rates, the population’s risk profile, the cost
of the vaccine, and whether future medical costs for additional
years of life gained were included in the calculations.
Vaccines intervention for the control of endemic Burkholderia
spp. should also be targeted where the most reliable estimates of
the incidence of Burkholderia spp. infections occur. The high-risk
groups such as diabetics and those with chronic kidney or lung
disease could be considered as primary targets for Burkholderia
spp. vaccine trials. In addition, occupational risk populations
which include farmers, construction workers, and military per-
sonnel also need to be considered as target groups. Taking the
occupational and economic-based evaluation into consideration,
there is a necessity for the vaccine to be used in a low income
community since Burkholderia spp. infections are also known as
the “poor man’s disease.”
Among the high-risk populations, in the community of an
endemic area, vaccination against Burkholderia pathogens can be
associated with less frequent hospitalizations and with direct sav-
ings in health care costs. Overall, this will reduce the burden of
the government in terms of health care cost. Reduction in disease
severity alone would be predicted to improve outcome in view of
the high mortality rate. However, one disadvantage may be that
generating protective immunity in individuals with such underly-
ing diseases may be difficult to achieve since several Burkholderia
spp. infections spread from person-to-person. Emergency mea-
sures should be taken as part of the biodefense efforts by focusing
on increasing the awareness amongst the medical community,
improving the diagnostic capabilities and preparation of national
response protocols. It has been suggested that vaccinating the
risk group against Burkholderia spp. infections is more cost effec-
tive than many other preventive and therapeutic interventions
(Peacock et al., 2012).
FUTURE DIRECTION
Despite different studies and strategies being used to iden-
tify effective vaccine candidates for Burkholderia spp., to date,
no reliable and conveniently measured correlates of vaccine-
induced efficacy against these bacteria and/or other intracellular
pathogens have been identified. Most importantly, researchers
have been unable to identify and measure the immune responses
that may be used to predict vaccines that will protect against the
intracellular pathogens. While some of the vaccine candidates are
able to induce substantial humoral response, some lacked the
ability to evoke strong cellular immune responses or the ability
to protect against infection with the Burkholderia spp. Perhaps,
better understanding of the specific mechanisms by which mem-
bers of the Burkholderia spp. subvert host defenses and survive
intracellularly will provide a stronger platform for identification
of an effective vaccine candidate. Another limiting factor is the
difficulties in generating protective immunity in immunocom-
promised individuals with underlying diseases such as diabetes
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and chronic lung disease may be difficult to achieve. Such correla-
tion would extensively aid in the design of new vaccines for Gram-
negative intracellular pathogens in general and Burkholderia spp.
in specific.
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